Drug
Diquafosol clinical trials
- studies test it
- 7
- open now
- 2
- in phase 3
- 1
- first study started
- 2002
Keep track of what changes. Save the diquafosol studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
Studies by the year they started
7 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2014 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 3
- 1
- Phase 4
- 2
- No phase
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 1 · Other 6
He Eye Hospital (2) · Korea University Anam Hospital (1) · Tianjin Eye Hospital (1) · Soonchunhyang University Hospital (1) · Merck Sharp & Dohme LLC (1) · Peking University Third Hospital (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses diquafosol is read from its arms, and is right about nine times in ten.
Testing it · 7
- Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients With Dry Eye After LASIKNot yet recruitingNot applicableHe Eye HospitalNCT07097922Written as 3% Diquafosol Sodium Eye Drops
- Compare the Clinical Efficacy of 3% Diquafosol and 0.1% Hyaluronic Acid in Patients with Dry Eye After Trans-PRKNot yet recruitingNot applicableHe Eye HospitalNCT06852105Written as 3% Diquafosol Sodium Eye Drops
- Immediate Therapeutic Effects of Diquafosol and Rebamipide in Dry Eye DiseaseCompletedPhase 4Korea University Anam HospitalNCT07297316Written as 3% diquafosol (right eye) and 2% rebamipide (left eye)
- Ditefossol Sodium 3% Eye Drops in Patients With Dry EyeCompletedNot applicableTianjin Eye HospitalNCT06560580Written as 3% Diquafosol Sodium Eye Drops
- The Effect of 3% Diquafosol Ophthalmic Solution on Visual Display Terminal-associated Dry EyeStatus unknownPhase 4Peking University Third HospitalNCT04668118Written as Diquafosol
- Clinical Effects and Safety of 3% Diquafosol After Cataract SurgeryCompletedNot applicableSoonchunhyang University HospitalNCT02608489Written as Diquafosol (Diquas)
- Study of INS365 Ophthalmic Solution in a Controlled Adverse Environment in Patients With Dry EyeCompletedPhase 3Merck Sharp & Dohme LLCNCT00037661Written as INS365 Ophthalmic Solution
Given in every arm · 2 — diquafosol is usual care beside what is tested
- To Evaluate the Efficacy of Diquafosol Sodium in the Treatment of MGD in Different Treatment PatternRecruitingNot applicableZhongshan Ophthalmic Center, Sun Yat-sen UniversityNCT05383612Written as 3% Diquafosol Sodium Eye Drops
- Study of DE-089 Ophthalmic Solution in Patients With Dry EyeCompletedNot applicableSanten Pharmaceutical Co., Ltd.NCT01101984Written as diquafosol ophthalmic solution
As the comparator · 2 — what is tested is compared with diquafosol
- Rebamipide Versus Diquafosol for Perioperative Dry Eye in Cataract SurgeryNot yet recruitingPhase 4Samsung Medical CenterNCT07397949Written as Diquafosol 3% ophthalmic solution
- Rebamipide Versus Diquafosol and Cyclosporine for Perioperative Dry Eye in Cataract SurgeryCompletedPhase 4Samsung Medical CenterNCT07397936Written as Diquafosol 3% ophthalmic solution
Codes
What other systems call diquafosol · ClinicalTrials.gg INT004205
- MeSH (NLM) C403315diquafosolOne source NLM
- UNII (FDA) 7828VC80FJDIQUAFOSOLConfirmed FDA, NLM, Wikidata
- Wikidata Q5280143diquafosolConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65436DiquafosolOne source FDA
- DrugBank DB15919One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C403315 | diquafosol | One source NLM |
| UNII (FDA) | 7828VC80FJ | DIQUAFOSOL | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q5280143 | diquafosol | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65436 | Diquafosol | One source FDA |
| DrugBank | DB15919 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.